Positive Symptoms in Antipsychotic-naïve Schizophrenia are Associated with Increased Body Mass Index after Treatment
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: Weight gain is an important risk factor for morbidity and mortality among patients with schizophrenia. We speculated that positive symptoms, related to dopaminergic hyperactivity and altered mesolimbic function, are associated with weight gain. Methods: Twenty-two antipsychotic-naïve, first-episode patients with schizophrenia were enrolled. The Positive and Negative Syndrome Scale was completed at enrollment and follow-up. Body mass index (BMI) was also measured. Results: The increase in BMI, after 6.04 ± 2.16 years of follow-up, was associated with positive symptoms, but not negative symptoms, before treatment with antipsychotics in antipsychotic-naïve patients with schizophrenia. Conclusion: This finding implied that dopaminergic hyperactivity could be an important factor to predict the treatment outcome. Body weight control is important for the health management of patients with schizophrenia with more severe positive symptoms.
Abstract
Objective: Weight gain is an important risk factor for morbidity and mortality among patients with schizophrenia. We speculated that positive symptoms, related to dopaminergic hyperactivity and altered mesolimbic function, are associated with weight gain. Methods: Twenty-two antipsychotic-naïve, first-episode patients with schizophrenia were enrolled. The Positive and Negative Syndrome Scale was completed at enrollment and follow-up. Body mass index (BMI) was also measured. Results: The increase in BMI, after 6.04 ± 2.16 years of follow-up, was associated with positive symptoms, but not negative symptoms, before treatment with antipsychotics in antipsychotic-naïve patients with schizophrenia. Conclusion: This finding implied that dopaminergic hyperactivity could be an important factor to predict the treatment outcome. Body weight control is important for the health management of patients with schizophrenia with more severe positive symptoms.
참고문헌 (22)
- Brisch R, "The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective : old fashioned, but still in vogue", Front Psychiatry, 5, pp.47~ (2014)
- de Greef R, "Dopamine D2 occupancy as a biomarker for antipsychotics : quantifying the relationship with efficacy and extrapyramidal symptoms", AAPS J, 13, pp.121~130 (2011)
- Howes OD, "A neurobiological hypothesis for the classification of schizophrenia : type A(hyperdopaminergic)and type B(normodopaminergic)", Br J Psychiatry, 205, pp.1~3 (2014)
- Kapur S, "Relationship between dopamine D2 occupancy, clinical response, and side effects : a double-blind PET study of first-episode schizophrenia", Am J Psychiatry, 157, pp.514~520 (2000)
- Howes OD, "Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia : insights from PET and SPECT imaging", Curr Pharm Des, 15, pp.2550~2559 (2009)
- Baptista T, "Body weight gain induced by antipsychotic drugs : mechanisms and management", Acta Psychiatr Scand, 100, pp.3~16 (1999)
- Manu P, "Weight gain and obesity in schizophrenia : epidemiology, pathobiology, and management", Acta Psychiatr Scand, 132, pp.97~108 (2015)
- Bai YM, "Association of initial antipsychotic response to clozapine and long-term weight gain", Am J Psychiatry, 163, pp.1276~1279 (2006)
- Czobor P, "Antipsychotic-induced weight gain and therapeutic response : a differential association", J Clin Psychopharmacol, 22, pp.244~251 (2002)
- Ascher-Svanum H, "Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia", BMC Psychiatry, 5, pp.3~ (2005)
- Grimm O, "Altered reward anticipation: potential explanation for weight gain in schizophrenia?", Neurosci Biobehav Rev, 75, pp.91~103 (2017)
- Nielsen MØ, "Striatal reward activity and antipsychotic-associated weight change in patients with schizophrenia undergoing initial treatment", JAMA Psychiatry, 73, pp.121~128 (2016)
- Hermes E, "The association between weight change and symptom reduction in the CATIE schizophrenia trial", Schizophr Res, 128, pp.166~170 (2011)
- Koga M, "Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved", Acta Psychiatr Scand, 112, pp.75~76 (2005)[DOI]
- Tseng HH, "Dopamine transporter availability in drug-naïve patients with schizophrenia and later psychotic symptoms severity", Schizophr Res, 190, pp.185~186 (2017)
- Yang YK, "Associated alterations of striatal dopamine D2", D3 receptor and transporter binding in drug-naive patients with schizophrenia : a dual-isotope SPECT study, 2004, pp.161, 1496~1498
- Kay SR, "The positive and negative syndrome scale(PANSS)for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
- Rummel-Kluge C, "Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia : a systematic review and meta-analysis", Schizophr Res, 123, pp.225~233 (2010)
- Dayabandara M, "Antipsychotic-associated weight gain : management strategies and impact on treatment adherence", Neuropsychiatr Dis Treat, 13, pp.2231~2241 (2017)
- Pascoli V, "Sufficiency of mesolimbic dopamine neuron stimulation for the progression to addiction", Neuron, 88, pp.1054~1066 (2015)
- Koob GF, "Neurocircuitry of addiction", Neuropsychopharmacology, 35, pp.217~238 (2010)
- Mezquida G, "Inverse association between negative symptoms and body mass index in chronic schizophrenia", Schizophr Res, 192, pp.69~74 (2018)